The company also said it will repurchase an additional $1 billion of its common stock.Amgen (AMGN) said third-quarter net income was $221 million, or 83 cents per share compared with $84 million, or 31 cents per share a year ago, including a charge. Without the charge, third-quarter earnings would have increased by 26 percent over the year-ago period, the company said.
Analysts surveyed by First Call anticipated the company's earnings to come in at 78 cents a share.
Net sales were up for the quarter: $700.9 million from $598.3 million, a year ago. Sales of Epogen, the company's kidney dialysis therapy, rose 23 percent to $350 million from $285 million a year ago.
Amgen also said it has completed its previously announced $1 billion stock repurchasing program, which began last October.